In the news

An article published by Genetic Engineering & Biotechnology News (GEN) discusses advances in synthetic biology and the promise the field holds for biomanufacturing therapeutic proteins and vaccines.

The piece quotes Synthorx CEO Court Turner, who explains that conventional synthetic biology is limited to the standard genetic code, which uses the same 20 natural amino acids and can introduce at most one unnatural amino acid.

By introducing additional nucleotides in the genetic code, Synthorx has developed a method for working with 256 codons, which could translate into 172 unnatural amino acids to produce novel proteins for a wide variety of unique protein drugs that couldn’t otherwise by synthesized using naturally occurring codons alone.

Read more in GEN

Explore how Synthorx creates diverse proteins